Senkyunolide I 是一种口服有效且能透过血脑屏障的 Z-ligustilide (MS-H88965) 代谢物,可从 Ligusticum chuanxiong 中分离,能上调 p-Erk1/2、Nrf2/HO-1 并抑制 Caspase 3,从而减轻凋亡 (Apoptosis),并可提高小鼠痛阈、减少醋酸诱导的小鼠扭体反应,改善局灶性脑缺血再灌注损伤大鼠的神经功能缺损、减小梗死体积与脑水肿程度,还可在肾缺血再灌注小鼠模型中保护肾功能及结构完整性,因此可用于局灶性脑缺血再灌注损伤、偏头痛、肾缺血再灌注损伤的相关研究。
产品编号: MS-X55202 纯度: 99.37% CAS No.: 94596-28-8 分子式: C12H16O4 分子量: 224.26
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Senkyunolide I 是一种口服有效且能透过血脑屏障的 Z-ligustilide (MS-H88965) 代谢物,可从 Ligusticum chuanxiong 中分离,能上调 p-Erk1/2、Nrf2/HO-1 并抑制 Caspase 3,从而减轻凋亡 (Apoptosis),并可提高小鼠痛阈、减少醋酸诱导的小鼠扭体反应,改善局灶性脑缺血再灌注损伤大鼠的神经功能缺损、减小梗死体积与脑水肿程度,还可在肾缺血再灌注小鼠模型中保护肾功能及结构完整性,因此可用于局灶性脑缺血再灌注损伤、偏头痛、肾缺血再灌注损伤的相关研究。

生物实验数据

生物活性 Senkyunolide I is an orally effective Z-ligustilide (MS-H88965) metabolite capable of crossing the blood-brain barrier, can be isolated from Ligusticum chuanxiong, upregulates p-Erk1/2 and Nrf2/HO-1 while inhibiting Caspase 3, thereby attenuating apoptosis (Apoptosis), and can elevate the pain threshold and reduce acetic acid-induced writhing responses in mice, ameliorate neurological deficits and reduce infarct volume and cerebral edema in rats with focal cerebral ischemia-reperfusion injury, and protect renal function and structural integrity in a mouse model of renal ischemia-reperfusion injury, and is therefore applicable to research on focal cerebral ischemia-reperfusion injury, migraine, and renal ischemia-reperfusion injury.
IC50 & Target

ERK1

 

ERK2

 

Caspase 3

 

HO-1

 

体外研究
(In Vitro)

Senkyunolide I (25-100 μM) 可激活 Hek293T/pGF1-ARE 细胞中的 Nrf2/ARE 通路。
Senkyunolide I (100-300 μg/mL; H2O2 处理前) 可保护肾小管上皮细胞 HK2 免受 H2O2 诱导的活力丧失。

体内研究
(In Vivo)

Senkyunolide I (36-72 mg/kg;静脉注射;闭塞后 15 分钟单次给药) 对大鼠局灶性脑缺血再灌注损伤具有剂量依赖性神经保护作用。
Senkyunolide I (8-32 mg/kg;口服) 可剂量依赖性地提高小鼠的热痛阈值,其中 32 mg/kg 剂量在给药后最早 20 min 即可产生显著的阈值升高,16 mg/kg 剂量在给药后 360 min 时显示出显著效果。
Senkyunolide I (32 mg/kg;口服) 可显著减轻小鼠中醋酸诱导的内脏痛。

Animal Model: Sprague-Dawley (male, 250-300 g, transient middle cerebral artery occlusion for 2 hours followed by 24 hours of reperfusion)
Dosage: 36 mg/kg; 72 mg/kg
Administration: i.v.; single dose at 15 minutes post-occlusion
Result: Significantly reduced neurological deficit scores at 72 mg/kg (P < 0.05 vs.
vehicle); showed non-significant alleviation of motor function at 36 mg/kg.
Significantly reduced ipsilateral brain water content to 82.30% ± 0.91% at 72 mg/kg (P < 0.05 vs.
vehicle); resulted in non-significant reduction to 85.35% ± 1.29% at 36 mg/kg.
Reduced infarct volume to 35.70% ± 5.35% at 36 mg/kg (P < 0.05 vs.
vehicle); reduced infarct volume to 27.31% ± 2.40% at 72 mg/kg (P < 0.05 vs.
vehicle).
Reversed cerebral morphologic damage in cortices and hippocampus at both 36 mg/kg and 72 mg/kg, with more dramatic reduction of histopathological alterations at 72 mg/kg dose.
Significantly decreased cortical MDA levels (P < 0.05 vs.
vehicle) and significantly increased cortical SOD activities (P < 0.05 vs.
vehicle) at both 36 mg/kg and 72 mg/kg, with no significant differences between the two doses.
Significantly increased the p-Erk1/2/t-Erk1/2 ratio, and the protein levels of c-Nrf2, n-Nrf2, HO-1, and NQO1 (P < 0.05 vs.
vehicle) at both 36 mg/kg and 72 mg/kg; resulted in higher levels of these proteins at 72 mg/kg compared to 36 mg/kg (P < 0.05).
Significantly reversed the down-regulation of Bcl-2 and up-regulation of Bax induced by I/R injury (P < 0.05 vs.
vehicle), elevated the Bcl-2/Bax ratio (P < 0.05 vs.
vehicle), and significantly down-regulated cleaved caspase 3 and caspase 9 expression (P < 0.05 vs.
vehicle) at both 36 mg/kg and 72 mg/kg; more effectively reduced Bax protein levels at 72 mg/kg compared to 36 mg/kg (P < 0.05), with no significant differences between doses for caspase inhibition.
Animal Model: Kunming (female, 18-22 g)
Dosage: 8 mg/kg; 16 mg/kg; 32 mg/kg
Administration: p.o.; single dose
Result: Elevated pain thresholds to 28.0 ± 7.0 s, 32.0 ± 7.3 s, and 35.5 ± 7.3 s at 20, 180, and 240 min post-administration for 32 mg/kg dose (P < 0.05 vs control).
Elevated pain threshold to 28.5 ± 6.9 s at 360 min post-administration for 16 mg/kg dose (P < 0.05 vs control).
Did not produce significant pain threshold elevations at any time point for 8 mg/kg dose.\nReduced the number of abdominal writhing responses to 18.8 ± 4.4 for 32 mg/kg dose (P < 0.05 vs control).
Did not produce significant reductions in writhing responses for 8 mg/kg and 16 mg/kg doses.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 224.26
分子式 C12H16O4
CAS No. 94596-28-8

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (8.92 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (445.91 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM4.4591 mL22.2956 mL44.5911 mL111.4778 mL
5 mM0.8918 mL4.4591 mL8.9182 mL22.2956 mL
10 mM0.4459 mL2.2296 mL4.4591 mL11.1478 mL
15 mM0.2973 mL1.4864 mL2.9727 mL7.4319 mL
20 mM0.2230 mL1.1148 mL2.2296 mL5.5739 mL
25 mM0.1784 mL0.8918 mL1.7836 mL4.4591 mL
30 mM0.1486 mL0.7432 mL1.4864 mL3.7159 mL
40 mM0.1115 mL0.5574 mL1.1148 mL2.7869 mL
50 mM0.0892 mL0.4459 mL0.8918 mL2.2296 mL
60 mM0.0743 mL0.3716 mL0.7432 mL1.8580 mL
80 mM0.0557 mL0.2787 mL0.5574 mL1.3935 mL
100 mM0.0446 mL0.2230 mL0.4459 mL1.1148 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础